BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28597653)

  • 1. Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
    Wu CP; Murakami M; Hsiao SH; Chou AW; Li YQ; Huang YH; Hung TH; Ambudkar SV
    Mol Pharm; 2017 Jul; 14(7):2368-2377. PubMed ID: 28597653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines.
    Wu CP; Hung CY; Lusvarghi S; Huang YH; Tseng PJ; Hung TH; Yu JS; Ambudkar SV
    Biochem Pharmacol; 2020 Oct; 180():114137. PubMed ID: 32634436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines.
    Wu CP; Hung CY; Hsieh YJ; Murakami M; Huang YH; Su TY; Hung TH; Yu JS; Wu YS; Ambudkar SV
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual effects of the PI3K inhibitor ZSTK474 on multidrug efflux pumps in resistant cancer cells.
    Muthiah D; Callaghan R
    Eur J Pharmacol; 2017 Nov; 815():127-137. PubMed ID: 28912036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
    Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
    Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
    Wang L; Lin N; Li Y
    Oncol Rep; 2019 Mar; 41(3):1678-1690. PubMed ID: 30664164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CC-115, a Dual Mammalian Target of Rapamycin/DNA-Dependent Protein Kinase Inhibitor in Clinical Trial, Is a Substrate of ATP-Binding Cassette G2, a Risk Factor for CC-115 Resistance.
    Beebe J; Zhang JT
    J Pharmacol Exp Ther; 2019 Nov; 371(2):320-326. PubMed ID: 31455631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCG2 Mediates Resistance to the Dual EGFR and PI3K Inhibitor MTX-211 in Cancer Cells.
    Wu CP; Hung CY; Murakami M; Wu YS; Chu YH; Huang YH; Yu JS; Ambudkar SV
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
    Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
    Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.
    To KK; Tomlinson B
    Br J Pharmacol; 2013 Nov; 170(5):1137-51. PubMed ID: 24032744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells.
    Wu ZX; Mai Q; Yang Y; Wang JQ; Ma H; Zeng L; Chen ZS; Pan Y
    Biomed Pharmacother; 2021 Apr; 136():111223. PubMed ID: 33450491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
    Walls M; Baxi SM; Mehta PP; Liu KK; Zhu J; Estrella H; Li C; Zientek M; Zong Q; Smeal T; Yin MJ
    Clin Cancer Res; 2014 Feb; 20(3):631-43. PubMed ID: 24240111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
    Yuan J; Mehta PP; Yin MJ; Sun S; Zou A; Chen J; Rafidi K; Feng Z; Nickel J; Engebretsen J; Hallin J; Blasina A; Zhang E; Nguyen L; Sun M; Vogt PK; McHarg A; Cheng H; Christensen JG; Kan JL; Bagrodia S
    Mol Cancer Ther; 2011 Nov; 10(11):2189-99. PubMed ID: 21750219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.